Noevir Holdings (4928) · RiskDropped
Voluntary Recall of Medicinal Throat Lozenges and Recall Loss
First written in FY2016-Q3. 1 of 2 entries say "Dropped", first in FY2017. Latest entry: FY2017.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Recognition of a provision for product-recall-related lossesA theme 19 companies write about · 20 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2020: 3 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.Full recordFilings, disclosures and news, newest first
- FY2017DroppedAnnual report
「Pharmaceuticals and food products performed steadily.」
The performance discussion for the current consolidated fiscal year does not mention the previous voluntary recall of medicated throat lozenges or the ¥559 million loss. - FY2016-Q3First statedAnnual report
「The company announced on 19 January 2016 the voluntary recall of medicated throat lozenges sold by its consolidated subsidiary Tokiwa Pharmaceutical Co., Ltd. A loss of ¥559 million related to the voluntary recall was recognized in the nine-month period of the current consolidated fiscal year.」
A voluntary product recall actually occurred, and a loss of ¥559 million was recognized.